Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 440 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06539169Recruiting
Following people with rare diseases over time
This study follows people with rare diseases over time to learn more about how these conditions progress and how they are treated. Joining may help researchers understand your disease better and find better ways to care for others.
Los Altos, CaliforniaAges Any age - NCT06552845Recruiting
Heart scan to guide atrial fibrillation treatment
This trial uses a special MRI scan to see if heart scarring matches low-voltage areas detected during catheter ablation for atrial fibrillation. If the scan results are consistent, it could help doctors better plan ablation procedures.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06564740Recruiting
Stem cell therapy for infants with biliary atresia and cirrhosis
This study is testing whether stem cells can help infants with liver cirrhosis from biliary atresia (a blocked bile duct condition) who have already had Kasai surgery. It aims to see if stem cell therapy can improve liver function and reduce complications.
Istanbul, IstanbulAges 2 months–18 years - NCT06567990Recruiting
Type 2 diabetes and fatty liver: new tests for disease tracking
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
DijonAges 40–80 - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75 - NCT06592820Recruiting
Ultrasound stiffness test for fatty liver disease
This study uses a special ultrasound technique, called shear wave elastography, to measure liver stiffness during an endoscopic ultrasound (EUS) procedure. It aims to see how well this new method detects liver scarring (fibrosis) in people with fatty liver disease, compared to standard tests like FibroScan and liver biopsy.
Boston, MassachusettsAges 18 years+ - NCT06599892Recruiting
Cystic fibrosis care with highly effective modulators
This study looks at how cystic fibrosis care is organized when patients take highly effective CFTR modulator drugs. It aims to understand if care needs change for those on modulators compared to those who cannot take them.
LyonAges 6 years+ - NCT04509050Recruiting
Testing a highly effective CF medicine in young children
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
Birmingham, AlabamaAges Up to 10 years - NCT06602869Recruiting
Cellular markers in cystic fibrosis with a certain lung infection
This study looks at special blood markers in people with cystic fibrosis who have or haven't been treated for a lung infection caused by nontuberculous mycobacteria. The goal is to better understand the body's response, which could lead to better treatments.
MontpellierAges 18 years+ - NCT06603246RecruitingPhase 1
Study of inhaled GDC-6988 for mucus lung diseases
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
Birmingham, AlabamaAges 18 years+ - NCT06604273RecruitingPhase 2/Phase 3
Studying bowel scarring in ulcerative colitis with filgotinib
This trial tests if filgotinib can help reduce intestinal scarring in people with active ulcerative colitis. It aims to understand fibrosis and find better ways to monitor treatment.
Amsterdam, North HollandAges 18 years+ - NCT06604260RecruitingPhase 2
PET scan to measure inflammation in Crohn's and colitis
This trial uses a special PET scan called FAPi-PET to look for inflammation and scarring in the gut. It may help doctors better understand your condition and guide treatment.
Amsterdam, North HollandAges 18 years+ - NCT06615492Recruiting
Lung transplant study: comparing two ECMO methods
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06619106Recruiting
Screening tool for minimal hepatic encephalopathy
This study tests a new cognitive tool to quickly and reliably detect minimal hepatic encephalopathy, a subtle brain change that can occur in people with liver disease. If you have a liver condition like fibrosis or cirrhosis and are already scheduled for a full evaluation (neuropsychological tests, MRI, EEG, and blood ammonia), this tool could help simplify future screening.
ParisAges 18–70 - NCT06654752Recruiting
Simpler treatment for lung flare-ups in kids with CF
This study tests a streamlined approach to managing sudden lung symptoms (pulmonary exacerbations) in children with cystic fibrosis. It aims to see if a simpler treatment plan works as well as standard care, which could mean less time in the hospital and fewer disruptions to daily life.
Birmingham, AlabamaAges 3–18 - NCT06655480RecruitingPhase 2
Triple drug therapy for advanced heart failure with preserved ejection fraction
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
MoscowAges 40–80 - NCT06683092Recruiting
Restarting triple therapy with close monitoring for side effects
This trial tests whether carefully restarting a triple-combination CFTR modulator (VTD) is safe and helpful for people with cystic fibrosis who had to stop or change Trikafta because of mental health side effects or liver injury. You will be closely monitored with surveys and daily diaries to ensure your safety.
Birmingham, AlabamaAges 6 years+ - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT06751069Recruiting
Home exercise and coaching for lung scarring
This study tests a home-based exercise and health coaching program for people with scarring in their lungs (fibrotic ILD). The goal is to see if doing rehab at home, with support from a coach, can help you feel better and breathe easier.
Scottsdale, ArizonaAges 18 years+ - NCT06756230Recruiting
Downhill walking exercise for IPF patients
This study tests whether downhill walking improves lung function and exercise ability in people with idiopathic pulmonary fibrosis (IPF). If you can walk on a treadmill and haven't been in a structured exercise program recently, you may qualify.
Istanbul, ÜsküdarAges 18–75 - NCT06776419Recruiting
Heart inflammation and scarring in Fabry disease
This study uses advanced heart scans (PET/CT and MRI) to look at inflammation, blood vessel health, and scarring in the hearts of people with Fabry disease. It aims to better understand how Fabry disease affects the heart and find new ways to track or treat these changes.
CopenhagenAges 18 years+ - NCT06797206Recruiting
CF in pregnancy and child health study
This study follows women with cystic fibrosis (CF) during pregnancy and after birth, and checks on their babies and young children. The goal is to learn more about how CF affects pregnancy and child development.
LondonAges Any age - NCT06801743Recruiting
When is a cardiac MRI helpful for extra heartbeats?
This study looks at when a cardiac MRI is most useful for people with extra heartbeats called premature ventricular complexes. It helps doctors understand if the MRI gives them important information beyond standard heart tests.
SalouëlAges 18 years+ - NCT06810167RecruitingPhase 3
Testing tenapanor for cystic fibrosis-related constipation
This study tests whether the drug tenapanor can help people with cystic fibrosis who have constipation. It may be an option for those whose current treatments are not working well.
Boston, MassachusettsAges 18–75
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 440 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.